My career in the oligonucleotide world began 1985 in the Research Group of Nobel Laureate Prof. Harald zur Hausen at the German Cancer Research Center in Heidelberg, Germany, when setting-up the the first core-facility for oligonucleotide manufacturing in Europe. At the same time I was complimenting my background in Chemistry with Virology and Molecular Biology;
1990-1993: Development of a DNA synthesiser and a DNA sequencer as member of the research group of Brian Sproat at EMBL, Heidelberg, Germany
1993-1994: One year sabbatical at Loyola University, Chicago, IL, conducting Papillomavirus-related cancer research;
1994-1998: Development of Ribozymes (therapeutic Hammerheads) manufacturing processes at Innovir GmbH, Göttingen, Germany, one of the early companies developing therapeutic oligonucleotides;
1998-2002: Setup of the Spiegelmer (enantiomeric therapeutic Aptamer) manufacturing, QC and automation labs at Noxxon Pharma AG, Berlin, Germany.
2002-2010: Global Field Application Specialist for oligonucleotide related products at GE Healthcare Europe.
2010-2013: Internal Subject Matter Expert for the large scale oligonucleotide CMO Girindus, Cincinnati, USA;
2013 – Independent CMC consultant at Thomas Rupp Consulting UG;
2021 – Managing Director, Axolabs Berlin GmbH.
